No Data
Hong Kong stocks fluctuated | Medical device stocks rose in early trading, with micro-invasive stocks leading the gains. The National Medical Products Administration said it would spare no effort in promoting the research and development innovation of med
Medical device stocks collectively rose. As of the time of publication, Siasun Robot&Automation-B (02252) rose by 11.46% to HK$7.22; Microport (00853) rose by 8.48% to HK$4.99; AK Medical (01789) rose by 5.73% to HK$4.06; Microport Neurotech (02172) rose by 2.38% to HK$7.75; Weigao Group (01066) rose by 2.09% to HK$4.40.
Weigao Group (01066) fell by 18.20%, now at 4.240 yuan, hitting a 52-week low.
As of 11:48, Weigao Group (01066) has dropped by 18.20% compared to the previous closing price, now trading at 4.240 yuan, hitting a 52-week low; the volume is 9.5705 million shares, with a turnover of 40.7507 million Hong Kong dollars.
Buy Recommendation: Undervalued Shandong Weigao Group Poised for Growth Amidst Healthcare Demand Surge
Hong Kong stocks are volatile | Weigao Group (01066) fell more than 8% in the morning, with first-half revenue and profit falling below expectations. UBS Group and CICC both lowered the company's target price.
Weigao Group (01066) fell more than 8% in the morning session. As of the time of writing, it has fallen 6.35% to HKD 4.13, with a turnover of 14.4557 million HKD.
HK$6.74: That's What Analysts Think Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Is Worth After Its Latest Results
Daiwa: Weigao Group rated 'In sync with the overall market', target price lowered to 5.1 Hong Kong dollars
Morgan Stanley released a research report stating that after Weigao Group (01066) announced its interim results, it continued to predict a 4% annual sales growth rate for the company over the next three years, which is slightly conservative compared to the company's sales growth guidance of 5% to 10% in 2024. At the same time, the earnings forecast for 2024 was raised by 1.2%, while the earnings forecast for 2025 and 2026 was reduced by 0.9% and 3% respectively, resulting in a compound annual growth rate of 3% for the three years. Considering the uncertain regulatory backdrop, the weighted average cost of capital assumption was increased from 10.5% to 11%. The target price was lowered from HKD 5.5 to 5.
Shareholders in Shandong Weigao Group Medical Polymer (HKG:1066) Are in the Red If They Invested Three Years AgoNo Data
No Data
